An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures
- Registration Number
- NCT01407523
- Lead Sponsor
- UCB Japan Co. Ltd.
- Brief Summary
To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
- Subject is a male or female aged ≥ 16 years
- Subject has Partial Onset Seizures that are classifiable according to the 1981 International League Against Epilepsy (ILAE) classification of Epileptic Seizures
- Subject weighs ≥ 40 kg
- Subject is currently taking Levetiracetam (LEV) as an adjunctive antiepileptic oral treatment with 1 to 3 other Antiepileptic Drugs (AEDs)
- Subject has problems with venous accessibility
- Subject has participated in another clinical/pharmacological study during the last 4 weeks prior to the Screening Visit
- Subject is pregnant or lactating
- Subject has a history of suicide attempt(s) or presents with current depressive signs, current suicidal ideation, and/or behavior
- Subject has clinically significant Electrocardiogram (ECG) abnormalities according to the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Levetiracetam Levetiracetam Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
- Primary Outcome Measures
Name Time Method Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days) During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18) An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days) During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18) A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, results in significant or persistent disability/incapacity, is a congenital anomaly/birth defect (including that occurring in a fetus), or is an important medical event that may jeopardize the subject or may require medical or surgical intervention.
- Secondary Outcome Measures
Name Time Method Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1 Day 1 Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4 Day 4 Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1 Day 1 Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.
Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows:
Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4 Day 4 Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.
Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows:
Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period During the Evaluation Period (Day 1 to Day 4) Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.
Trial Locations
- Locations (4)
1
🇯🇵Niigata-city, Niigata, Japan
2
🇯🇵Shizuoka-city, Shizuoka, Japan
3
🇯🇵Kodaira-city, Tokyo, Japan
4
🇯🇵Yamagata-city, Yamagata, Japan